Phenominer Database Results (32 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Clinical Measurement Notes Record ID Study ID
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 12 0.16 cm 0.0 0.01 echocardiography 0.0 0 101786 2641
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 12 986.71 mg 25.23 87.4 echocardiography 0.0 0 101798 2641
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 12 0.34 g/cm 0.0 0.0 post excision weight measurement 0.0 0 101758 2641
SS.ZUC-Leprfa-/-/Slc pancreas weight to tibia length everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 12 29.85 mg/mm 1.97 6.82 post excision weight measurement 0.0 0 p/tl 101836 2641
SS.ZUC-Leprfa-/-/Slc urine total protein level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. total urine protein amount male 91 days 12 13.37 mg/ml 0.97 3.35 urine protein analysis 0.0 0 101872 2641
SS.ZUC-Leprfa-/-/Slc creatinine clearance to body weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 12 0.17 ml/min/100g 0.02 0.07 serum creatinine analysis 0.0 0 101880 2641
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 12 334.74 mg/mm 9.21 31.9 post excision weight measurement 0.0 0 rf/tl 101774 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 9 0.65 mmHg/mm 0.05 0.15 echocardiography 0.0 0 lvedp/lvdd 101832 2641
SS.ZUC-Leprfa-/-/Slc ejection fraction everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 12 76.47 % 1.2 4.16 echocardiography 0.0 0 101812 2641
SS.ZUC-Leprfa-/-/Slc serum triglyceride level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood triglyceride amount male 91 days 12 1251.33 mg/dl 276.6 958.17 serum triglyceride analysis 0.0 0 101852 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 12 38.55 % 1.09 3.78 echocardiography 0.0 0 101808 2641
SS.ZUC-Leprfa-/-/Slc E wave deceleration time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 12 35.82 ms 0.68 2.36 echocardiography 0.0 0 101820 2641
SS.ZUC-Leprfa-/-/Slc liver weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 12 568.94 mg/mm 19.5 67.55 post excision weight measurement 0.0 0 liv/tl 101766 2641
SS.ZUC-Leprfa-/-/Slc blood high density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood HDL cholesterol amount male 91 days 12 67.83 mg/dl 15.23 52.76 blood cholesterol analysis 0.0 0 101844 2641
SS.ZUC-Leprfa-/-/Slc serum creatinine level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood creatinine amount male 91 days 12 0.37 mg/dl 0.03 0.1 serum creatinine analysis 0.0 0 101876 2641
SS.ZUC-Leprfa-/-/Slc serum free fatty acids level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood free fatty acid amount male 91 days 12 19.47 mmol/l 1.16 4.02 serum free fatty acid analysis 0.0 0 **suspected wrong units in paper(mg/dl) 101856 2641
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 12 765.81 mg/mm 23.86 82.65 post excision weight measurement 0.0 0 if/tl 101782 2641
SS.ZUC-Leprfa-/-/Slc single kidney weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 12 25.22 g/cm 0.65 2.26 post excision weight measurement 0.0 0 101770 2641
SS.ZUC-Leprfa-/-/Slc epididymal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 12 2.43 g/cm 0.1 0.35 post excision weight measurement 0.0 0 ef/tl 101778 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 12 1.68 mm 0.05 0.17 echocardiography 0.0 0 101794 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 12 41.0 % 1.0 3.46 echocardiography 0.0 0 101804 2641
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 12 28.77 ms 1.73 5.99 echocardiography 0.0 0 101828 2641
SS.ZUC-Leprfa-/-/Slc serum urea nitrogen level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood urea nitrogen amount male 91 days 12 27.42 mg/dl 1.23 4.26 serum urea nitrogen analysis 0.0 0 101868 2641
SS.ZUC-Leprfa-/-/Slc creatinine clearance to total kidney weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 12 0.28 ml/min/g 0.04 0.14 serum creatinine analysis 0.0 0 101884 2641
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 12 34.39 ms 1.07 3.71 echocardiography 0.0 0 101824 2641
SS.ZUC-Leprfa-/-/Slc blood alanine aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood alanine transaminase amount male 91 days 12 46.67 U/l 2.44 8.45 automated blood analysis 0.0 0 101864 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 12 8.05 mm 0.07 0.24 echocardiography 0.0 0 101790 2641
SS.ZUC-Leprfa-/-/Slc E/A wave ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 12 1.91 null 0.07 0.24 echocardiography 0.0 0 e/a 101816 2641
SS.ZUC-Leprfa-/-/Slc blood aspartate aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood aspartate transaminase amount male 91 days 12 65.6 U/l 7.65 26.5 automated blood analysis 0.0 0 101860 2641
SS.ZUC-Leprfa-/-/Slc blood total cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood cholesterol amount male 91 days 12 297.67 mg/dl 35.78 123.95 blood cholesterol analysis 0.0 0 101840 2641
SS.ZUC-Leprfa-/-/Slc blood low density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood LDL cholesterol amount male 91 days 12 38.17 mg/dl 1.53 5.3 blood cholesterol analysis 0.0 0 101848 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 12 0.25 g/cm 0.0 0.01 post excision weight measurement 0.0 0 lv/tl 101762 2641